Medical Condition News

RSS

Younger women with metastatic colorectal cancer live longer than younger men

Younger women with metastatic colorectal cancer lived longer than younger men. However, this survival advantage disappeared with age, suggesting a benefit from estrogen or other hormones, according to results of a study published in Clinical Cancer Research, a journal of the American Association for Cancer Research.

30 Sep 2009

Soybeans can prevent heart disease and cancer

Soybeans contain high levels of several health-beneficial compounds including tocopherols, which have antioxidant properties. These molecules can be used in the development of functional foods, which have specific health-beneficial properties and can be used in the treatment or prevention of diseases.

30 Sep 2009

One third of women avoid routine mammogram tests

On the eve of Breast Cancer Awareness Month, Cancer Research UK today sends out a warning that if thousands of women continue to ignore invitations to breast screening they could be putting their lives at risk.

30 Sep 2009

Study: Role of genetics and environment in autism spectrum disorders

Researchers at The University of Texas Health Science Center at Houston and the University of the West Indies have joined forces to launch a study of Jamaican children that they hope will unlock the secrets of how genetics and environment may interact to cause autism spectrum disorders.

29 Sep 2009

MabCures develops monoclonal antibodies against Colorectal Cancer

MabCure, Inc., a biotechnology company that has developed a series of highly specific monoclonal antibodies (MAbs) to combat various types of cancers, has reached another development milestone, with the creation of its MAbs against Colorectal Cancer (CRC). After further characterization the company plans to explore the utility of these MAbs in terms of both the early diagnosis of CRC (in blood or feces specimens), as well as imaging agents for detecting micrometastatic disease during surgery and the detection of cancerous polyps during colonoscopy.

29 Sep 2009

Response Genetics launches new genetic diagnostic test for gastric cancer

Response Genetics, Inc., a company focused on the development and sale of molecular diagnostic tests for cancer, announced today the availability of its ResponseDX: Gastric™ genetic test panel, a proprietary PCR-based diagnostic test. By analyzing the expression of genes that correlate with response to commonly used chemotherapy agents, physicians can better tailor treatment for their patients with gastric cancer and gastroesophageal (GE) junction cancer.

29 Sep 2009

Vitae receives 11Beta-HSD-1 program milestone payment from Boehringer Ingelheim

Vitae Pharmaceuticals, Inc., an integrated discovery and development company, today announced that it has earned an $8 million milestone payment from Boehringer Ingelheim for achievement of a performance milestone in their 11beta-hydroxysteroid dehydrogenase (HSD)-1 diabetes and metabolic disease strategic alliance.

29 Sep 2009

SAIC-Frederick and Roche collaborate on technology advancements in sequencing cancer genes

National Cancer Institute contractor SAIC-Frederick, Inc., a wholly owned subsidiary of Science Applications International Corporation, and Roche Applied Science, a division of Roche Diagnostics Corporation, have signed a collaboration agreement to assess Roche’s advanced technologies to sequence the genomes of cancer research samples.

From Roche Sequencing and Life Science 29 Sep 2009

AAP receives grant to promote awareness on childhood obesity

The American Academy of Pediatrics (AAP) announces that it has been awarded a $250,000 grant from MetLife Foundation, to promote community and regional approaches to obesity prevention. Through the grant, AAP will launch two national grant programs, which are focused on encouraging both established pediatricians and pediatricians-in-training to develop collaborative methods to educate communities about the health effects of childhood obesity.

29 Sep 2009

San Francisco Medical Center acquires a BSD-500 Hyperthermia System

BSD Medical Corporation announced today that the University of California, San Francisco Medical Center (UCSF) has acquired a BSD-500 Hyperthermia System (BSD-500). UCSF is a world leader in hyperthermia and has the largest and most versatile hyperthermia program on the West Coast, and its world-renowned Radiation Oncology team has added the capabilities of the BSD-500 to its growing hyperthermia cancer treatment program.

29 Sep 2009

pSivida reports interim results of human PK study of Iluvien

pSivida Corp, a leading drug delivery company that has developed two of the only three products approved by the FDA for the long-term, sustained release delivery of drug to treat chronic back of the eye disease, today reported the interim 18-month safety and efficacy results from the first human pharmacokinetic study (PK Study) of Iluvien®. The PK trial is being conducted by Alimera Sciences, the licensee for Iluvien.

29 Sep 2009

Synta commences Phase 1/2 clinical study of novel Hsp90 inhibitor in hematologic malignancies

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that it has initiated a Phase 1/2 clinical study of its novel heat shock protein 90 (Hsp90) inhibitor, STA-9090 in hematologic malignancies with a once-a-week dosing schedule.

29 Sep 2009

Aurora Breast MRI and Clear Channel Radio join to support The Wellness Community fundraiser

Aurora Breast MRI of Sarasota today announced it has partnered with Clear Channel Radio for a fundraising effort to benefit The Wellness Community of Southwest Florida. The fundraiser, titled “Change for Change,” will consist of a series of breast cancer awareness messages throughout the month of October to encourage donations at area “Change for Change” locations.

29 Sep 2009

Multiple Sclerosis Society of Canada invites schools to participate in the 32nd MS Read-A-Thon

Multiple Sclerosis Society of Canada, Quebec Division is happy to announce the 32nd edition of the MS Read-A-Thon. This event invites students in elementary and secondary schools across the province to participate in an enjoyable activity that gives them a chance to develop their philanthropic qualities while stimulating their interest in reading.

29 Sep 2009

Dynavax commences Phase 3 trial for HEPLISAV hepatitis B vaccine

Dynavax Technologies Corporation (Nasdaq:DVAX) today announced the initiation of a Phase 3 registration trial for HEPLISAVTM hepatitis B vaccine in individuals with chronic kidney disease. A second registration trial, a Phase 3 lot-to-lot consistency trial, is expected to begin in early 2010. HEPLISAV is an investigational adult hepatitis B vaccine designed to provide increased, rapid protection with fewer doses than current licensed vaccines.

29 Sep 2009

2009 Mini-Psych School Program dispels myths surrounding mental illness

The Mental Illness Awareness Week is coming up, from October 4 to 10. On this occasion, Joseph Rochford, Ph.D., Director of the Academic Affairs at the Douglas Mental Health University Institute, presents his top ten list of myths about mental illness.

29 Sep 2009

Diabetics should monitor their blood sugar levels to improve metabolic status

Diabetes patients should always control their own blood sugar values if this leads to improvements in their treatment. This is the view advocated by Michael Nauck of the Bad Lauterberg Diabetes Center and his coauthors in the current issue of Deutsches Ärzteblatt International (Dtsch Arztebl Int 2009; 106[37]: 587-94), who discuss sensible approaches to blood glucose self-monitoring.

29 Sep 2009

New microchip to detect type and severity of cancer

UofT researchers have used nanomaterials to develop a microchip sensitive enough to quickly determine the type and severity of a patient's cancer so that the disease can be detected earlier for more effective treatment.

29 Sep 2009

Benefits and harms of screening infants for hyperbilirubinemia still unclear

According to a new recommendation from the U.S. Preventive Services Task Force, there is insufficient evidence to assess the balance of benefits and harms of screening infants for hyperbilirubinemia to prevent chronic bilirubin encephalopathy. Hyperbilirubinemia is a condition marked by a high level of bilirubin in the blood, which is often apparent as yellow-colored skin and eyes (jaundice).

29 Sep 2009

Januvia in combination with metformin or taken alone lowers blood sugar

A post-hoc analysis, presented at the 45th Annual Meeting of the European Association for the Study of Diabetes (EASD), of data pooled from studies of 104 weeks in duration showed ‘Januvia’ (sitagliptin), when taken alone or in combination with metformin, provided significant blood sugar lowering over two years.

29 Sep 2009